1st Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for SAFE RX

Period 1st Quarter 2017 Filed Apr 20, 2017 Signed by Marc S. Lampkin, Attorney at Law

Official filing
Firm
BROWNSTEIN HYATT FARBER SCHRECK, LLP
Client
SAFE RX
Income
$10,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Educating policy makers about anti-filfering technology know as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs Implementation of PL 114-328, Comprehensive Addiction and Recovery Act of 2016 Implementation of PL 114-198, National Defense Authorization Act for fiscal year 2017-Title III, Secttion 301, Evidence based prescription opiod and heroin treatment and interventions demonstration

LobbyistCovered position, as disclosed
PETER M. GOODLOE —
WILLIAM MOSCHELLA —

Contacted: Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.